Prolonged Inappropriate TSH Suppression During Hypothyroidism After Thyroid Ablation in a Patient with Nonautoimmune Familial Hyperthyroidism

Abstract

Prolonged TSH suppression was reported in a patient with nonautoimmune hyperthyroidism. These observations were made during L-thyroxine treatment and it was not possible to investigate a possible increase in serum TSH concentrations to levels observed in untreated hypothyroidism. We describe nonautoimmune familial hyperthyroidism identified in an Israeli woman, which is remarkable for the prolonged inappropriate TSH suppression after thyroid ablation. After 2 radioiodine treatments for several years, her TSH was always lower than 0.03 mU/l with 1.6 μg/kg/day (100 μg) thyroxine. 14 years after the radioiodine treatments, she discontinued thyroxine for 3.5 months and developed myxoedema with fT4 <6.0 and fT3 1.3 pmol/l and TSH of only 4.4 mU/l, which rose to only 8.6 after TRH. Genomic analysis showed a germline substitution M626I in the TSHR gene. Both exons of the thyroid-releasing hormone receptor revealed no mutations in this gene. Functional in vitro characterization of M626I showed a cell surface expression of 70% compared with the wt (100%), a significant increase of basal activity (5-fold over wt basal), which was confirmed by linear regression analysis (LRA) (slope: M626I=7, wt=1). No TRH-receptor mutation was detected. Therefore, this is the first patient with nonautoimmune hyperthyroidism with unequivocal evidence for inappropriately prolonged TSH suppression documented by a clearly insufficient TSH increase during clinical hypothyroidism. The in vitro characterization of the TSH-receptor mutation did not show any explanations for the prolonged TSH suppression. Therefore, other possible candidate genes remain to be investigated for potential explanations for this prolonged TSH suppression.

Key words

constitutively activating mutation - hypothyroidism - thyroid stimulating hormone receptor

References

• 1 Brownlie BE, Legge HM. Thyrotropin results in euthyroid patients with a past history of hyperthyroidism.  Acta Endocrinol (Copenh). 1990;  122 623-627
• 2 Uy HL, Reasner CA, Samuels MH. Pattern of recovery of the hypothalamic-pituitary-thyroid axis following radioactive iodine therapy in patients with Graves’ disease.  Am J Med. 1995;  99 173-179
• 3 Brokken LJ, Scheenhart JW, Wiersinga WM, Prummel MF. Suppression of serum TSH by Graves’ Ig: evidence for a functional pituitary TSH receptor.  J Clin Endocrinol Metab. 2001;  86 4814-4817
• 4 Brokken LJ, Wiersinga WM, Prummel MF. Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves’ disease patients.  J Clin Endocrinol Metab. 2003;  88 4135-4138
• 5 Ross DS, Daniels GH, Gouveia D. The use and limitations of a chemiluminescent thyrotropin assay as a single thyroid function test in an out-patient endocrine clinic.  J Clin Endocrinol Metab. 1990;  71 764-769
• 6 Sanchez-Franco F, Garcia MD, Cacicedo L, Martin-Zurro A, Escobar dR, Morreale dE. Transient lack of thyrotropin (TSH) response to thyrotropin-releasing hormone (TRH) in treated hyperthyroid patients with normal or low serum thyroxine (T4) and triiodothyronine (T3).  J Clin Endocrinol Metab. 1974;  38 1098-1102
• 7 Serhal DI, Nasrallah MP, Arafah BM. Rapid rise in serum thyrotropin concentrations after thyroidectomy or withdrawal of suppressive thyroxine therapy in preparation for radioactive iodine administration to patients with differentiated thyroid cancer.  J Clin Endocrinol Metab. 2004;  89 3285-3289
• 8 Gelwane G, de Roux N, Chevenne D, Carel JC, Leger J. Pituitary-thyroid feedback in a patient with a sporadic activating thyrotropin (TSH) receptor mutation: implication that thyroid-secreted factors other than thyroid hormones contribute to serum TSH levels.  J Clin Endocrinol Metab. 2009;  94 2787-2791
• 9 Trulzsch B, Krohn K, Wonerow P, Paschke R. DGGE is more sensitive for the detection of somatic point mutations than direct sequencing.  Biotechniques. 1999;  27 988
• 10 Jäschke H, Neumann S, Moore S, Thomas CJ, Colson AO, Costanzi S, Kleinau G, Jiang JK, Paschke R, Raaka BM, Krause G, Gershengorn MC. A low molecular weight agonist signals by binding to the transmembrane domain of thyroid-stimulating hormone receptor (TSHR) and luteinizing hormone/chorionic gonadotropin receptor (LHCGR).  J Biol Chem. 2006;  281 9841-9844
• 11 Mueller S, Gozu HI, Bircan R, Jaeschke H, Eszlinger M, Lueblinghoff J, Krohn K, Paschke R. Cases of borderline in vitro constitutive thyrotropin receptor activity: how to decide whether a thyrotropin receptor mutation is constitutively active or not?.  Thyroid. 2009;  19 765-773
• 12 Jaeschke H, Kleinau G, Sontheimer J, Mueller S, Krause G, Paschke R. Preferences of transmembrane helices for cooperative amplification of G(alpha)s and G (alpha)q signaling of the thyrotropin receptor.  Cell Mol Life Sci. 2008;  65 4028-4038
• 13 Kopp P, van Sande J, Parma J, Duprez L, Gerber H, Joss E, Jameson JL, Dumont JE, Vassart G. Brief report: congenital hyperthyroidism caused by a mutation in the thyrotropin-receptor gene.  N Engl J Med. 1995;  332 150-154
• 14 Grüters A, Schöneberg T, Biebermann H, Krude H, Krohn HP, Dralle H, Gudermann T. Severe congenital hyperthyroidism caused by a germ-line neo mutation in the extracellular portion of the thyrotropin receptor.  J Clin Endocrinol Metab. 1998;  83 1431-1436
• 15 Holzapfel HP, Wonerow P, von Petrykowski W, Henschen M, Scherbaum WA, Paschke R. Sporadic congenital hyperthyroidism due to a spontaneous germline mutation in the thyrotropin receptor gene.  J Clin Endocrinol Metab. 1997;  82 3879-3884
• 16 Watkins MG, Dejkhamron P, Huo J, Vazquez DM, Menon RK. Persistent neonatal thyrotoxicosis in a neonate secondary to a rare thyroid-stimulating hormone receptor activating mutation: case report and literature review.  Endocr Pract. 2008;  14 479-483
• 17 Borgel K, Pohlenz J, Koch HG, Bramswig JH. Long-term carbimazole treatment of neonatal nonautoimmune hyperthyroidism due to a new activating TSH receptor gene mutation (Ala428Val).  Horm Res. 2005;  64 203-208
• 18 Ringkananont U, Van Durme J, Montanelli L, Ugrasbul F, Yu YM, Weiss RE, Refetoff S, Grasberger H. Repulsive separation of the cytoplasmic ends of transmembrane helices 3 and 6 is linked to receptor activation in a novel thyrotropin receptor mutant (M626I).  Mol Endocrinol. 2006;  20 893-903
• 19 Fuhrer D, Lachmund P, Nebel IT, Paschke R. The thyrotropin receptor mutation database: Update 2003.  Thyroid. 2003;  13 1123-1126
• 20 Bray GA, Goodman HM. Metabolism of adipose tissue from normal and hypothyroid rats.  Endocrinology. 1968;  82 860-864
• 21 Carlé A, Laurberg P, Pedersen IB, Perrild H, Ovesen L, Rasmussen LB, Jorgensen T, Knudsen N. Age modifies the pituitary TSH response to thyroid failure.  Thyroid. 2007;  17 139-144
• 22 Moeller LC, Alonso M, Liao X, Broach V, Dumitrescu A, Van Sande J, Montanelli L, Skjei S, Goodwin C, Grasberger H, Refetoff S, Weiss RE. Pituitary-thyroid setpoint and thyrotropin receptor expression in consomic rats.  Endocrinology. 2007;  148 4727-4733
• 23 Andersen S, Pedersen KM, Bruun NH, Laurberg P. Narrow individual variations in serum T(4) and T(3) in normal subjects: a clue to the understanding of subclinical thyroid disease.  J Clin Endocrinol Metab. 2002;  87 1068-1072
• 24 Hansen PS, Brix TH, Iachine I, Sorensen TI, Kyvik KO, Hegedus L. Genetic and environmental interrelations between measurements of thyroid function in a healthy Danish twin population.  Am J Physiol Endocrinol Metab. 2007;  292 E765-E770
• 25 Meikle AW, Stringham JD, Woodward MG, Nelson JC. Hereditary and environmental influences on the variation of thyroid hormones in normal male twins.  J Clin Endocrinol Metab. 1988;  66 588-592
• 26 Arnaud-Lopez L, Usala G, Ceresini G, Mitchell BD, Pilia MG, Piras MG, Sestu N, Maschio A, Busonero F, Albai G, Dei M, Lai S, Mulas A, Crisponi L, Tanaka T, Bandinelli S, Guralnik JM, Loi A, Balaci L, Sole G, Prinzis A, Mariotti S, Shuldiner AR, Cao A, Schlessinger D, Uda M, Abecasis GR, Nagaraja R, Sanna S, Naitza S. Phosphodiesterase 8B gene variants are associated with serum TSH levels and thyroid function.  Am J Hum Genet. 2008;  82 1270-1280
• 27 Panicker V, Wilson SG, Spector TD, Brown SJ, Kato BS, Reed PW, Falchi M, Richards JB, Surdulescu GL, Lim EM, Fletcher SJ, Walsh JP. Genetic loci linked to pituitary-thyroid axis set points: a genome-wide scan of a large twin cohort.  J Clin Endocrinol Metab. 2008;  93 3519-3523
• 28 Peeters RP, van der Deure WM, Visser TJ. Genetic variation in thyroid hormone pathway genes; polymorphisms in the TSH receptor and the iodothyronine deiodinases.  Eur J Endocrinol. 2006;  155 655-662
• 29 Sykiotis GP, Neumann S, Georgopoulos NA, Sgourou A, Papachatzopoulou A, Markou KB, Kyriazopoulou V, Paschke R, Vagenakis AG, Papavassiliou AG. Functional significance of the thyrotropin receptor germline polymorphism D727E.  Biochem Biophys Res Commun. 2003;  301 1051-1056
• 30 Castanet M, Carre A, Tron E, de Roux, Cabrol S, Puel O, Queinnec C, Leger J, Polak M. Phenotypic Variability of PAX8 Mutations in congenital Hypothyroidism a Digenism Hypothesis with Potential Role of TSHR.  Acta Médica Portuguesa 34th Meeting of the European Thyroid Association (ETA). 2009;  22 (1) 3637 Abstract
• 31 Kursawe R, Paschke R. Modulation of TSHR signaling by posttranslational modifications.  Trends Endocrinol Metab. 2007;  18 199-207
• 32 Prummel MF, Brokken LJ, Meduri G, Misrahi M, Bakker O, Wiersinga WM. Expression of the thyroid-stimulating hormone receptor in the folliculo-stellate cells of the human anterior pituitary.  J Clin Endocrinol Metab. 2000;  85 4347-4353

Correspondence